Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AYTU 
Aytu BioScience Inc (AYTU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AYTU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9
1 Year Target Price $9
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.17% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.85M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 0.05 | 52 Weeks Range 0.95 - 2.96 | Updated Date 06/30/2025 |
52 Weeks Range 0.95 - 2.96 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.01% | Operating Margin (TTM) 13.12% |
Management Effectiveness
Return on Assets (TTM) -0.59% | Return on Equity (TTM) -3.06% |
Valuation
Trailing PE - | Forward PE 23.31 | Enterprise Value 22098519 | Price to Sales(TTM) 0.23 |
Enterprise Value 22098519 | Price to Sales(TTM) 0.23 | ||
Enterprise Value to Revenue 0.27 | Enterprise Value to EBITDA 2.08 | Shares Outstanding 8976910 | Shares Floating 4579927 |
Shares Outstanding 8976910 | Shares Floating 4579927 | ||
Percent Insiders 7.58 | Percent Institutions 27.32 |
Analyst Ratings
Rating 1 | Target Price 9 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aytu BioScience Inc
Company Overview
History and Background
Aytu BioScience Inc. was founded in 2009 and is a specialty pharmaceutical company focused on commercializing novel products that address significant medical needs. The company has undergone several acquisitions and name changes over the years. It has focused on men's health, pediatrics, and consumer health products.
Core Business Areas
- Prescription Products: Development and marketing of prescription drugs targeting specific medical conditions, primarily in men's health and pediatric areas. This includes products for attention deficit hyperactivity disorder (ADHD) and other therapeutic areas.
- Consumer Health Products: Sales and marketing of consumer healthcare products. This includes nutritional supplements, personal care items, and other over-the-counter (OTC) products.
Leadership and Structure
The company's leadership team consists of its Chief Executive Officer, Chief Financial Officer, and other key executives. The organizational structure typically includes departments for research and development, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Adzenys XR-ODT: A stimulant medication used to treat ADHD. Market share is difficult to determine precisely due to competition from other ADHD medications. Competitors include Teva Pharmaceuticals, Tris Pharma, and others offering stimulant ADHD medications. Revenue generated is not publically available from annual reports.
- Karvay: Indicated for the clinical dietary management of certain metabolic deficiencies. Market share data is not readily available. Competitors in this market include companies offering similar metabolic supplements. Revenue generated is not publically available from annual reports.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant R&D investment. The consumer health market is also highly competitive with numerous established players.
Positioning
Aytu BioScience Inc. occupies a niche position within the specialty pharmaceutical and consumer health markets. Its competitive advantage is difficult to determine, as the product lines are very competitive.
Total Addressable Market (TAM)
The pharmaceutical and consumer health markets represent hundreds of billions of dollars. Aytu BioScience's ability to capture a significant portion of this TAM depends on its product portfolio, marketing effectiveness, and competitive positioning.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio (prescription and consumer health)
- Established sales and marketing infrastructure
- Potential for strategic acquisitions to expand product offerings
Weaknesses
- High operating expenses
- Dependence on key products
- Limited R&D resources compared to larger pharmaceutical companies
- Historical operating losses and accumulated deficit
Opportunities
- Acquisition of complementary products or businesses
- Expansion into new geographic markets
- Strategic partnerships for product development and commercialization
- Capitalizing on unmet medical needs
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes impacting product approvals or reimbursement
- Product liability claims
- Patent expirations
Competitors and Market Share
Key Competitors
- TEVA
- VRX
- SHPG
Competitive Landscape
Aytu BioScience Inc. faces intense competition from larger, more established pharmaceutical companies with greater financial and R&D resources. To compete effectively, it must focus on niche markets, strategic acquisitions, and effective marketing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been a combination of acquisitions and organic growth within the company's product segments.
Future Projections: Future growth projections are highly variable and dependent on product performance, regulatory approvals, and market conditions. Analyst estimates should be reviewed.
Recent Initiatives: Aytu BioScience Inc. has focused on acquiring and commercializing new products to drive growth.
Summary
Aytu BioScience Inc. is a specialty pharmaceutical company with a diverse product portfolio, though it operates in a highly competitive market. Its strengths lie in its sales infrastructure and potential for strategic acquisitions. However, it faces challenges related to high operating expenses and competition from larger companies. The company needs to focus on strategic initiatives to drive growth and improve profitability. Overall, the company is weak and faces many challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aytu BioScience Inc
Exchange NASDAQ | Headquaters Denver, CO, United States | ||
IPO Launch date 2017-02-01 | CEO & Director Mr. Joshua R. Disbrow | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 102 | Website https://aytubio.com |
Full time employees 102 | Website https://aytubio.com | ||
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above, and Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.